Navigation Links
FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer
Date:10/19/2009

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved VOTRIENT(TM) (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. Approximately 57,700 people in the U.S. will be diagnosed with kidney cancer this year, and 13,000 people will die from this disease.

"RCC is the most common malignancy of the kidney and is highly resistant to chemotherapy," said Paolo Paoletti, MD, Senior Vice President, GlaxoSmithKline Oncology R&D Unit. "While treatment has improved in the past few years with the introduction of targeted therapies, advanced RCC remains a challenging disease. VOTRIENT will join existing targeted therapies to provide physicians with a new oral treatment option to their patients with advanced renal cell cancer."

VOTRIENT, a once-daily, oral medication, is an angiogenesis inhibitor which may help prevent the growth of new blood vessels, thereby blocking the growth of kidney cancer tumors that need blood vessels to survive.

The approval of VOTRIENT was supported by a unanimous decision by the FDA's Oncology Drugs Advisory Committee (ODAC) that the benefit-to-risk profile for VOTRIENT is acceptable for patients with advanced kidney cancer. The ODAC reviewed data from a Phase III clinical trial showing that VOTRIENT reduced the risk of tumor progression or death by 54 percent compared to placebo, regardless of prior treatment.

In this Phase III trial, the overall median PFS was 9.2 months with pazopanib and 4.2 months with placebo. Treatment-naive patients who received VOTRIENT experienced 11.1 months of median progression-free survival (PFS) versus 2.8 months with placebo. Additionally, patients who had previously received cytokine-based treatment achieved 7.4 mo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
2. FDA Approves New Treatment for Advanced Form of Kidney Cancer
3. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
4. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
5. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
6. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
7. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
10. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
11. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
(Date:8/29/2014)... Aug. 29, 2014  In part four ... a hospital pharmacy as a strategic asset, Mary ... leader for Cardinal Health,s Innovation Delivery Solutions business, discusses ... benefit both hospitals and patients. "Every hospital ... part of their job in a value-based healthcare world," ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... RALEIGH, N.C., Sept. 6, 2011 BioDelivery Sciences ... positive preliminary results from its Phase 1 study ...  BDSI is seeking to develop and commercialize a ... (abuse deterrent agent) for the treatment of opioid ...
... NEW YORK, Sept. 6, 2011 ... new market research report is ... Emerging Pharmaceutical Market ... Between Domestic and International Pharmaceutical ...
Cached Medicine Technology:BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 2BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 3BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 4Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 2Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 3Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 4Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 5Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 6Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 7Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 8Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 9Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 10Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force 11
(Date:8/29/2014)... 30, 2014 AGH Healthy Happenings, a ... Doctors in Delaware at Atlantic General Hospital, are ... services. In addition to no-cost blood pressure screenings at ... aid care at local sports tournaments. , In ... staff provide free disease management and falls prevention workshops ...
(Date:8/29/2014)... Daily Gossip reveals in its Get Rid of Cold ... cold sores patient who suffered from this terrible health problem for ... to share her tips and advices, but also her experience with ... the Get Rid of Cold Sores Fast program says that she ... least 4 years outbreaks have become more frequent. , Ellie ...
(Date:8/29/2014)... The new review that can be read ... holistic system that will permanently eliminate the symptoms of this ... can achieve a cure in as fast as 30 to ... only about one week. , The Tinnitus Miracle review ... as mild hearing loss, pain in the ear and dizziness. ...
(Date:8/29/2014)... 29, 2014 The Nasal Polyps ... that the new program is actually based on ... was created by a former nasal polyps sufferer, ... the disturbing problem. Manuel Richards suffered from nasal ... system. , Learn more about Manuel Richards' ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of ... monthly per-port licensing of its Q-Suite 5.7 software. ... Indosoft has been successfully deploying and supporting its ACD ... centers around the world for more than a decade. ... clients another option which complements the widespread deployment of ...
Breaking Medicine News(10 mins):Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3Health News:Get Rid of Cold Sores Fast Review Reveals Simple Way to Eliminate Cold Sores in 12 Hours 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2
... meat, starches and sweets is linked to a rise ... to a study by US and Chinese researchers released ... the 1990s Shanghai Breast Cancer Study by Vanderbilt University ... between higher incidence of breast cancer and a move ...
... Roche Holding AG says that arthritis drug Actemra has ... helps relieve symptoms of rheumatoid arthritis in difficult-to-treat ... to regulatory approval. ,The Radiate study was conducted ... Actemra was given in combination with a standard treatment ...
... folic acid fortification of enriched grains in the mid 1990s, ... and Canada with neural tube defects has declined by 20 ... institution of fortification, however, the rate at which new cases ... report researchers at the Jean Mayer USDA Human Nutrition Research ...
... hospital ranked as one of Americas Best by U.S. News ... days than those admitted to a non-ranked hospital , according ... of Internal Medicine, one of the JAMA/Archives journals. ... mortality measures that are publicly reported by the Centers for ...
... 9 issue of Archives of Internal Medicine, one of ... screen for prostate cancer are frequently performed among patients ... be beneficial, and clinicians with certain characteristics are more ... ,Most guidelines for clinical practice do not recommend routine ...
... a man of the times, throwing around terms like "eco-design" ... at the Bangkok home he designed for his family two ... only to be energy efficient but to produce energy -- ... of some of the brightest international names working in eco-architecture ...
Cached Medicine News:Health News:Folicacid Fortification Very Beneficial 2Health News:Folicacid Fortification Very Beneficial 3Health News:Americas Best Hospital Reduced Heart Attack Rates 2Health News:Americas Best Hospital Reduced Heart Attack Rates 3Health News:Clinicians Ordering Inappropriate Prostate Screenings 2Health News:Eco-architecture Takes Root in Thailand, but Growth is Slow 2Health News:Eco-architecture Takes Root in Thailand, but Growth is Slow 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: